Sansure Biotech Inc. (SHA:688289)

Sansure Biotech Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	4,399	4,590	4,233	3,213	2,636	2,591
Trading Asset Securities	103.59	139.67	548.28	2,451	2,046	1,601
Cash & Short-Term Investments	4,503	4,730	4,782	5,664	4,683	4,192
Cash Growth	-9.00%	-1.09%	-15.57%	20.95%	11.70%	2433.03%
Accounts Receivable	752.54	560.69	692.26	1,298	807.66	546.4
Other Receivables	38.87	27.58	23.49	82.41	14.3	17.55
Receivables	791.4	588.27	715.75	1,381	821.95	563.94
Inventory	363.76	392.75	376.63	355.31	369.5	276.74
Other Current Assets	118.33	78.7	75.45	125.83	92.09	50
Total Current Assets	5,776	5,790	5,950	7,525	5,966	5,083
Property, Plant & Equipment	1,256	1,113	1,043	785.27	481.03	216.54
Long-Term Investments	1,095	1,096	974.33	657.43	513.23	102.51
Goodwill	770.81	7.66	7.66	-	-	-
Other Intangible Assets	516.34	334.67	283.28	79.12	45.55	31.23
Long-Term Deferred Tax Assets	75.83	69.28	73.82	69.62	25	17.22
Long-Term Deferred Charges	148.89	147.27	97.05	46.7	16.26	4.16
Other Long-Term Assets	46.02	47.04	25.16	10.19	43.08	-
Total Assets	9,684	8,604	8,454	9,174	7,090	5,454
Accounts Payable	434.04	225.78	271.14	586.26	188.82	208.05
Accrued Expenses	103.21	290.03	363.33	622.39	231.82	237.88
Short-Term Debt	18	9	9	-	-	55
Current Portion of Leases	5.06	5.28	11.1	14.26	8.49	-
Current Income Taxes Payable	21.83	0.21	17.66	145.25	80.16	104.17
Current Unearned Revenue	41.18	64.55	32.81	53.11	78.64	62.47
Other Current Liabilities	677.93	159.94	214.12	150.45	76.01	21.11
Total Current Liabilities	1,301	754.8	919.15	1,572	663.93	688.69
Long-Term Debt	810.16	396.65	-	-	-	-
Long-Term Leases	11.44	11.92	18.21	13.6	6.41	-
Long-Term Unearned Revenue	38.19	39.88	32.49	30.53	25.68	18.95
Long-Term Deferred Tax Liabilities	90.38	54.75	59.45	19.04	13.01	1.31
Other Long-Term Liabilities	-	-	-	26.09	-	-
Total Liabilities	2,251	1,258	1,029	1,661	709.03	708.95
Common Stock	579.39	582.39	588.46	588.46	400	400
Additional Paid-In Capital	1,602	1,702	1,908	1,914	2,065	2,055
Retained Earnings	5,286	5,194	5,177	5,371	4,082	2,288
Treasury Stock	-164.89	-274.29	-515.33	-392.6	-200.01	-
Comprehensive Income & Other	39.17	39.01	43.26	19.36	21.71	2.12
Total Common Equity	7,341	7,243	7,201	7,501	6,369	4,745
Minority Interest	91.46	102.56	223.64	12.16	12.43	-
Shareholders' Equity	7,433	7,346	7,425	7,513	6,381	4,745
Total Liabilities & Equity	9,684	8,604	8,454	9,174	7,090	5,454
Total Debt	844.66	422.85	38.31	27.86	14.9	55
Net Cash (Debt)	3,658	4,307	4,743	5,636	4,668	4,137
Net Cash Growth	-19.11%	-9.20%	-15.83%	20.74%	12.83%	2399.80%
Net Cash Per Share	6.25	7.35	8.09	9.63	7.93	7.49
Filing Date Shares Outstanding	574.18	573.72	573.52	578.69	592	592
Total Common Shares Outstanding	574.18	573.72	572.21	578.69	592	592
Working Capital	4,475	5,035	5,030	5,954	5,302	4,394
Book Value Per Share	12.79	12.62	12.59	12.96	10.76	8.02
Tangible Book Value	6,054	6,901	6,910	7,421	6,323	4,714
Tangible Book Value Per Share	10.54	12.03	12.08	12.82	10.68	7.96
Buildings	-	834.41	826.53	344.51	231.04	177.15
Machinery	-	607.96	436.62	322.65	270.13	142.76
Construction In Progress	-	3.58	4.59	267.76	110.45	1.85

Source: S&P Global Market Intelligence. Standard template. Financial Sources.